Olanzapine-Induced Mania: A Case Report with New Characteristics

Downloads

Published

2024-06-03

DOI:

https://doi.org/10.54169/ijocp.v4i01.104

Keywords:

Olanzapine, antipsychotics, mania, induced

Dimensions Badge

Issue

Vol. 4 No. 01 (2024): Indian Journal of Clinical Psychiatry

Section

CASE REPORT

License

Copyright (c) 2024 Mehdi Aghamohammadi, Mahsa Ghasemi

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Authors

  • Mehdi Aghamohammadi Department of Internal Medicine, School of Medicine, Vali-e-Asr Hospital, Zanjan University of Medical Sciences, Zanjan, Iran
  • Mahsa Ghasemi Department of Psychiatry, School of Medicine, Shahid Beheshti Hospital, Zanjan University of Medical Sciences, Zanjan, Iran

Abstract

Abstract olanzapine is an atypical antipsychotic widely used for the treatment of mania as monotherapy. In this case, it paradoxically caused mania symptoms in a 40-year-old patient with intermittent explosive disorder. This case presents different characteristics from previous reports, suggesting a direct link between olanzapine and mania symptoms. The patient did not have any psychotic or mood disorder, and the symptoms rapidly disappeared during a medication-free period. Furthermore, there was no discontinuation of other medications, no prominent family history of psychiatric disorder, and no addiction to substances, all of which suggest a connection between manic symptoms and olanzapine. Possible receptor and genomic explanations for this phenomenon are also discussed.

How to Cite

Aghamohammadi, M., & Ghasemi, M. (2024). Olanzapine-Induced Mania: A Case Report with New Characteristics. Indian Journal of Clinical Psychiatry, 4(01), 103–107. https://doi.org/10.54169/ijocp.v4i01.104

Downloads

Download data is not yet available.

References

References

Butler M, Urosevic S, Desai P, Sponheim SR, Popp J, Nelson VA, Thao V, Sunderlin B. Treatment for Bipolar Disorder in Adults: A Systematic Review [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Aug. Report No.: 18-EHC012-EF. PMID: 30329241.

Erhel F, Scanff A, Naudet F. The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports. Epidemiology and Psychiatric Sciences. 2020;29:e120. doi:10.1017/S2045796020000359

Yatham LN, Kennedy SH, Parikh SV, Schaffer A, Bond DJ, Frey BN, Sharma V, Goldstein BI, Rej S, Beaulieu S, Alda M, MacQueen G, Milev RV, Ravindran A, O'Donovan C, McIntosh D, Lam RW, Vazquez G, Kapczinski F, McIntyre RS, Kozicky J, Kanba S, Lafer B, Suppes T, Calabrese JR, Vieta E, Malhi G, Post RM, Berk M. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018 Mar;20(2):97-170. doi: 10.1111/bdi.12609. Epub 2018 Mar 14. PMID: 29536616; PMCID: PMC5947163

Kadakia A, Dembek C, Heller V, Singh R, Uyei J, Hagi K, Nosaka T, Loebel A. Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis. BMC Psychiatry. 2021 May 11;21(1):249. doi: 10.1186/s12888-021-03220-3. PMID: 33975574; PMCID: PMC8112003

Benyamina A, Samalin L. Atypical antipsychotic-induced mania/hypomania: a review of recent case reports and clinical studies. Int J Psychiatry Clin Pract. 2012 Mar;16(1):2-7. doi: 10.3109/13651501.2011.605957. Epub 2011 Aug 31. PMID: 22122647.

Côrte-Real B, Saraiva R, Cordeiro CR, Frey BN, Kapczinski F, de Azevedo Cardoso T. Atypical antipsychotic-induced mania: A systematic review and meta-analysis. J Affect Disord. 2023 Jul 15;333:420-435. doi: 10.1016/j.jad.2023.04.037. Epub 2023 Apr 20. PMID: 37084970.

Michalopoulou PG, Lykouras L. Manic/hypomanic symptoms induced by atypical antipsychotics: a review of the reported cases. Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jun;30(4):549-64. doi: 10.1016/j.pnpbp.2005.11.026. Epub 2006 Jan 25. PMID: 16442194.

Benazzi F. Olanzapine-induced psychotic mania in bipolar schizo-affective disorder. European Psychiatry. 1999;14(7):410-410. doi:10.1016/S0924-9338(99)00227-8

Lane HY, Lin YC, Chang WH. Mania induced by risperidone: dose related? J Clin Psychiatry. 1998 Feb;59(2):85-6. doi: 10.4088/jcp.v59n0207f. PMID: 9501895.

Raghunath A. Repeated activation of mania by atypical antipsychotics in a patient. BMJ Case Rep. 2012 Nov 27;2012:bcr2012007388. doi: 10.1136/bcr-2012-007388. PMID: 23188864; PMCID: PMC4543567.

Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999 Feb;156(2):286-93. doi: 10.1176/ajp.156.2.286. PMID: 9989565.

Ichikawa J, Ishii H, Bonaccorso S, Fowler WL, O'Laughlin IA, Meltzer HY. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem. 2001 Mar;76(5):1521-31. doi: 10.1046/j.1471-4159.2001.00154.x. PMID: 11238736 ا

Pilla M, Perachon S, Sautel F, Garrido F, Mann A, Wermuth CG, Schwartz JC, Everitt BJ, Sokoloff P. Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. Nature. 1999 Jul 22;400(6742):371-5. doi: 10.1038/22560. Erratum in: Nature 1999 Sep 23;401(6751):403. PMID: 10432116.Chantal Henry case report in 2002

Henry C, Demotes-Mainard J. Olanzapine-induced mania in bipolar disorders. J Psychiatry Neurosci. 2002 May;27(3):200-1. PMID: 12066449; PMCID: PMC161651.Bertolino et al., 2004

Yazici O, Kora K, Polat A, Saylan M. Controlled lithium discontinuation in bipolar patients with good response to long-term lithium prophylaxis. J Affect Disord. 2004 Jun;80(2-3):269-71. doi: 10.1016/S0165-0327(03)00133-2. PMID: 15207941.

Bertolino A, Caforio G, Blasi G, De Candia M, Latorre V, Petruzzella V, Altamura M, Nappi G, Papa S, Callicott JH, Mattay VS, Bellomo A, Scarabino T, Weinberger DR, Nardini M. Interaction of COMT (Val(108/158)Met) genotype and olanzapine treatment on prefrontal cortical function in patients with schizophrenia. Am J Psychiatry. 2004 Oct;161(10):1798-805. doi: 10.1176/ajp.161.10.1798. PMID: 15465976.

Similar Articles

1 2 > >> 

You may also start an advanced similarity search for this article.